Ubs Group Ag Rocket Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 647,830 shares of RCKT stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

647,830

Previous 569,963 13.66%

Holding current value

$1.79 Million

Previous $7.16 Million 39.68%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$6.67 - $12.72 $519,372 - $990,468	77,867 Added 13.66%	647,830 $4.32 Million
Q4 2024 Feb 14, 2025	BUY	$11.35 - $18.82 $2.63 Million - $4.36 Million	231,829 Added 68.56%	569,963 $7.16 Million
Q3 2024 Nov 14, 2024	SELL	$17.6 - $25.88 $1.19 Million - $1.75 Million	-67,648 Reduced 16.67%	338,134 $6.25 Million
Q2 2024 Aug 13, 2024	SELL	$20.66 - $26.72 $2.13 Million - $2.76 Million	-103,172 Reduced 20.27%	405,782 $8.74 Million
Q1 2024 May 13, 2024	BUY	$26.16 - $30.74 $12.2 Million - $14.3 Million	466,150 Added 1089.03%	508,954 $13.7 Million
Q4 2023 Feb 09, 2024	SELL	$16.78 - $31.94 $3.61 Million - $6.88 Million	-215,425 Reduced 83.42%	42,804 $1.28 Million
Q3 2023 Nov 09, 2023	BUY	$15.07 - $24.05 $3.48 Million - $5.55 Million	230,812 Added 841.86%	258,229 $5.29 Million
Q2 2023 Aug 11, 2023	SELL	$16.59 - $23.6 $1.47 Million - $2.09 Million	-88,737 Reduced 76.4%	27,417 $544,000
Q1 2023 May 12, 2023	SELL	$15.79 - $22.6 $2.83 Million - $4.05 Million	-179,107 Reduced 60.66%	116,154 $1.99 Million
Q4 2022 Feb 08, 2023	BUY	$15.5 - $22.76 $3.07 Million - $4.51 Million	198,358 Added 204.7%	295,261 $5.78 Million
Q3 2022 Nov 10, 2022	BUY	$12.37 - $18.41 $372,534 - $554,435	30,116 Added 45.09%	96,903 $1.55 Million
Q2 2022 Aug 10, 2022	SELL	$7.96 - $16.64 $854,983 - $1.79 Million	-107,410 Reduced 61.66%	66,787 $919,000
Q1 2022 May 16, 2022	BUY	$13.16 - $23.68 $440,399 - $792,451	33,465 Added 23.78%	174,197 $2.76 Million
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $964,720 - $1.61 Million	44,829 Added 46.74%	140,732 $3.07 Million
Q3 2021 Nov 15, 2021	BUY	$27.42 - $48.97 $2.3 Million - $4.1 Million	83,742 Added 688.61%	95,903 $2.87 Million
Q2 2021 Aug 13, 2021	SELL	$39.41 - $47.25 $2.45 Million - $2.93 Million	-62,052 Reduced 83.61%	12,161 $539,000
Q1 2021 May 12, 2021	BUY	$43.34 - $65.91 $1.22 Million - $1.85 Million	28,048 Added 60.76%	74,213 $3.29 Million
Q4 2020 Feb 11, 2021	BUY	$23.3 - $59.57 $605,590 - $1.55 Million	25,991 Added 128.83%	46,165 $2.53 Million
Q3 2020 Nov 12, 2020	BUY	$20.5 - $28.59 $351,083 - $489,632	17,126 Added 561.88%	20,174 $461,000
Q2 2020 Jul 31, 2020	SELL	$13.32 - $22.61 $364,435 - $618,609	-27,360 Reduced 89.98%	3,048 $64,000
Q1 2020 May 01, 2020	SELL	$9.71 - $25.11 $249,605 - $645,477	-25,706 Reduced 45.81%	30,408 $425,000
Q4 2019 Feb 14, 2020	BUY	$11.07 - $24.23 $41,656 - $91,177	3,763 Added 7.19%	56,114 $1.28 Million
Q3 2019 Nov 14, 2019	BUY	$10.85 - $14.78 $507,552 - $691,393	46,779 Added 839.54%	52,351 $610,000
Q2 2019 Aug 14, 2019	BUY	$15.0 - $19.81 $83,430 - $110,183	5,562 Added 55620.0%	5,572 $84,000
Q1 2019 May 14, 2019	SELL	$13.45 - $19.01 $242,288 - $342,446	-18,014 Reduced 99.94%	10 $0
Q4 2018 Feb 14, 2019	BUY	$11.21 - $23.53 $145,830 - $306,101	13,009 Added 259.4%	18,024 $267,000
Q3 2018 Nov 14, 2018	BUY	$18.5 - $25.49 $25,456 - $35,074	1,376 Added 37.81%	5,015 $123,000
Q2 2018 Aug 14, 2018	BUY	$14.58 - $23.0 $30,049 - $47,403	2,061 Added 130.61%	3,639 $71,000
Q1 2018 May 15, 2018	BUY	$11.68 - $19.19 $18,431 - $30,281	1,578 New	1,578 $29,000

Others Institutions Holding RCKT

# of Institutions

258

Shares Held

108M

Call Options Held

555K

Put Options Held

177K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $210M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account